Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesEffector Therapeutics Inc

Effector Therapeutics Inc

Healthcare Biotechnology
PortfolioPortfolio WatchlistWatchlist
Company price
0.0008 USD 0.00(0%)
Last update at 2026-11-05T21:00:00Z
VOLUME
331
Market Cap
0.00M

Momentum Score

…

eFFECTOR Therapeutics, Inc., a biopharmaceutical company, engages in the development of selective translation regulator inhibitors for the treatment of cancer. The company's lead product candidate includes Zotatifin, an inhibitor of eIF4A, which is in Phase 1/2 clinical trial to treat patients with solid tumors, as well as has completed Phase 2 clinical trial in combination with fulvestrant and abemaciclib to treat patients with ER+ breast cancer. It also develops Tomivosertib, an oral small-molecule inhibitor of MNK that is in phase 2b clinical trial for the treatment of patients with metastatic non-small cell lung cancer. It has a research collaboration and license agreement with Pfizer Inc. to research and develop small molecules that target eIF4E. eFFECTOR Therapeutics, Inc. was founded in 2012 and is headquartered in Solana Beach, California.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
0.00
Low
0.00
High
52 Week Price Range
0.00
Low
0.00
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Effector Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing small-molecule therapeutics and advancing R&D and clinical programs. Long-term growth drivers may include positive clinical data readouts, regulatory approvals, and licensing or partnership deals that could support pipeline commercialization and value creation.
Primary investment risks include clinical trial failure risk, the need for additional financing with potential dilution, regulatory uncertainty, and strong competition in the drug development sector.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
0.00
Dividend Yield
-
Revenue TTM
0.68M
Revenue Per Share
0.35
Gross Profit TTM
-21.62M
Debt / Equity
-3.36
ROE
-946.56%
Net Debt
4.57M
ROCE
626.28%
Diluted EPS TTM
-12.57

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Income before tax -35.81M -22.66M 15.80M 14.56M -
Net income -35.81M -12.93M 15.80M 14.21M -
Selling general administrative 10.93M 12.64M 13.37M 4.35M -
Gross profit -0.11M - 1.43M 42.00M -
Reconciled depreciation 0.11M 0.05M 0.02M 0.16M -
Ebit -32.89M -32.46M -31.92M 15.82M -28.61M
Ebitda -32.78M -32.40M -31.90M 16.05M -
Depreciation and amortization 0.11M 0.05M 0.02M 0.24M -
Non operating income net other - - 49.46M - -
Operating income -33.84M -32.40M -31.90M 15.82M -
Other operating expenses 33.84M 32.40M 31.90M 26.18M -
Interest expense 2.92M 2.25M 1.76M 1.33M 0.00M
Tax provision - - 0.00M 0.35M -
Interest income 0.96M 0.44M 0.01M 0.07M -
Net interest income -1.90M -1.81M -1.76M -1.27M -
Income tax expense - -9.74M -0.02M 0.35M -
Total revenue 0.00M 0.00M 1.43M 42.00M -
Total operating expenses 33.84M 32.40M 31.90M 26.18M -
Cost of revenue 0.11M - - - -
Total other income expense net -1.97M 9.74M 47.70M -1.26M -
Net income from continuing ops -35.94M -22.66M 15.80M 14.21M -
Net income applicable to common shares - -22.66M 15.80M 0.17M -14.21M
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Total assets 20.54M 29.08M 54.06M 16.70M -
Other current assets 1.42M 1.70M 3.19M 1.36M -
Total liab 26.34M 25.18M 36.77M 148.95M -
Total stockholder equity -5.79M 3.90M 17.28M -132.25M -
Other current liab 4.02M 3.37M 3.42M 0.43M 0.44M
Common stock - 0.00M 0.00M 0.00M 0.00M
Capital stock 0.00M 0.00M 0.00M 0.00M -
Retained earnings -179.38M -143.57M -120.90M -136.70M -150.91M
Other liab - 0.05M 12.81M - -
Other assets 0.00M 0.71M 0.90M 0.18M -
Cash 14.88M 8.71M 49.70M 15.22M -
Total current liabilities 25.80M 25.07M 3.98M 8.78M 18.93M
Current deferred revenue - - - 1.98M -
Net debt 4.57M 11.57M -29.67M -2.25M -
Short term debt 19.45M 20.22M 0.04M 6.01M -
Short long term debt 20.48M 20.16M - 5.91M -
Short long term debt total 19.45M 20.28M 20.03M 12.96M -
Other stockholder equity 173.58M 147.48M 138.18M 4.45M -
Property plant equipment - 0.35M 0.09M 0.13M 0.82M
Total current assets 19.84M 28.01M 52.90M 16.58M 4.27M
Net tangible assets - 3.90M 17.28M -132.25M -147.06M
Short term investments 3.50M 17.60M - - -
Net receivables 0.05M 0.03M 0.10M - -
Long term debt - - 19.86M 6.95M -
Accounts payable 2.33M 1.49M 0.52M 0.35M 0.60M
Accumulated other comprehensive income 0.00M -0.02M -54.06M - -
Common stock total equity - - 0.00M 0.00M -
Retained earnings total equity - - -120.90M - -
Non currrent assets other 0.51M 0.71M 0.90M - -
Non current assets total 0.71M 1.06M 1.16M 0.13M -
Capital lease obligations 0.06M 0.12M 0.17M 0.11M -
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Investments 9.16M -17.86M 0.56M -0.15M -17.67M
Change to liabilities - 0.96M 1.95M -0.25M -0.73M
Total cashflows from investing activities 14.48M -17.86M 0.56M -0.15M 0.08M
Net borrowings - - 19.84M -2.00M -2.00M
Total cash from financing activities 21.23M 2.77M 58.81M -1.89M 20.24M
Change to operating activities - 1.72M -0.39M -0.57M 1.80M
Net income -35.81M -22.66M 15.80M 14.21M -14.21M
Change in cash 6.17M -40.99M 34.49M 11.79M -7.27M
Begin period cash flow 8.71M 49.70M 15.22M 3.43M -
End period cash flow 14.88M 8.71M 49.70M 15.22M 3.43M
Total cash from operating activities -29.55M -25.90M -24.89M 13.84M -27.60M
Issuance of capital stock 15.03M 2.80M - - -
Depreciation 0.11M 0.05M 0.02M 0.16M 0.31M
Other cashflows from investing activities - - 0.56M - -
Sale purchase of stock - - 0.06M - -
Other cashflows from financing activities 0.06M -0.03M 72.75M 0.11M -0.09M
Change to netincome - -5.96M 8.44M 14.33M -14.77M
Capital expenditures 0.10M 0.19M 0.04M 0.15M 0.00M
Cash flows other operating - - -51.09M - -
Cash and cash equivalents changes - - 34.49M - -
Change in working capital 1.69M 2.68M -0.24M -0.82M -
Stock based compensation 4.59M 5.33M 8.66M 0.50M -
Other non cash items -0.13M -11.30M -48.59M 0.12M -
Free cash flow -29.65M -26.09M -24.93M 13.68M -

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to EBITDA (x)
EFTR
Effector Therapeutics Inc		 -
-%		 0.00 - - 69.65 0.00 -0.41
NVO
Novo Nordisk A/S		 0.01
0.02%		 40.31 41.58 31.15 2.13 32.99 4.70
VRTX
Vertex Pharmaceuticals Inc		 4.59
0.85%		 547.09 30.22 24.27 10.36 6.50 24.66
REGN
Regeneron Pharmaceuticals Inc		 1.45
0.16%		 904.35 29.07 20.12 7.57 3.82 19.42
ARGNF
argenx SE		 -
-%		 900.30 45.77 31.25 13.84 7.12 36.06

Profile*

Effector Therapeutics Inc

eFFECTOR Therapeutics, Inc., a biopharmaceutical company, engages in the development of selective translation regulator inhibitors for the treatment of cancer. The company's lead product candidate includes Zotatifin, an inhibitor of eIF4A, which is in Phase 1/2 clinical trial to treat patients with solid tumors, as well as has completed Phase 2 clinical trial in combination with fulvestrant and abemaciclib to treat patients with ER+ breast cancer. It also develops Tomivosertib, an oral small-molecule inhibitor of MNK that is in phase 2b clinical trial for the treatment of patients with metastatic non-small cell lung cancer. It has a research collaboration and license agreement with Pfizer Inc. to research and develop small molecules that target eIF4E. eFFECTOR Therapeutics, Inc. was founded in 2012 and is headquartered in Solana Beach, California.

142 North Cedros Avenue, Solana Beach, CA, United States, 92075

858 925 8215

https://effector.com

14

Name Title Year Born
Dr. Stephen T. Worland Ph.D. CEO, Pres & Director 1958
Mr. Michael Byrnes M.B.A. Chief Financial Officer 1977
Dr. Siegfried Reich Ph.D. Co-Founder and Member of Clinical & Scientific Advisory Board 1960
Dr. Davide Ruggero Ph.D. Co-Founder and Member of Clinical & Scientific Advisory Board NA
Dr. Kevan M. Shokat Ph.D. Co-Founder and Member of Clinical & Scientific Advisory Board NA
Dr. Douglas Warner M.D. Chief Medical Officer NA
Dr. Mayank J. Gandhi M.D. Chief Bus. Officer 1978
Dr. Stephen T. Worland Ph.D. CEO, President & Director 1958
Dr. Douglas Warner M.D. Chief Medical Officer 1972

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

ITH
CAD 2.15
+27.68%
HG
CAD 4.11
+19.13%
PPTA
CAD 27.74
+17.99%
UCU
CAD 2.10
+17.32%
GAU
CAD 3.49
+16.72%
TSU
CAD 29.67
-29.71%
PXT
CAD 19.73
-16.91%
LAS-A
CAD 230.50
-9.25%
IFP
CAD 13.50
-8.35%
NFI
CAD 24.01
-7.80%

Equity Sectors*

  • Basic Materials

    +3.74%

  • Communication Services

    +0.56%

  • Consumer Cyclical

    -0.34%

  • Consumer Defensive

    +0.11%

  • Energy

    +1.33%

  • Financial Services

    -0.26%

  • Healthcare

    +2.54%

  • Industrials

    -0.11%

  • Real Estate

    -0.23%

  • Technology

    +1.91%

  • Utilities

    +1.05%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…